<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995345</url>
  </required_header>
  <id_info>
    <org_study_id>0104-005</org_study_id>
    <nct_id>NCT00995345</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone</brief_title>
  <acronym>Synergy104</acronym>
  <official_title>A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of Once-Daily KRP-104 in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ActivX Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyorin Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ActivX Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic
      control in patients with type 2 diabetes inadequately controlled on metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline (Week 0) to Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Mean Change in HbA1c (%) from Baseline to Week 24 with LOCF, ITT population LS mean (SE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean Change in Body Weight (kg) from Baseline to Week 24 with LOCF- ITT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving HbA1c Less Than 7%</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subjects Achieving Target of Hemoglobin A1c &lt;7.0% at Week 24 with LOCF - Intent-to-Treat Population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Requiring Rescue Therapy for Elevated Glucose</measure>
    <time_frame>24 weeks of treatment.</time_frame>
    <description>Percentage of Subjects Requiring Rescue Therapy - Intent-to-Treat Population</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dose 1: KRP-104 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, once-daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2: KRP-104 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, once-daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3: KRP-104 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, once-daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4: KRP-104 20/120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet, once-daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRP-104</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Dose 1: KRP-104 40 mg</arm_group_label>
    <arm_group_label>Dose 2: KRP-104 80 mg</arm_group_label>
    <arm_group_label>Dose 3: KRP-104 100 mg</arm_group_label>
    <arm_group_label>Dose 4: KRP-104 20/120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients meeting the following criteria at the screening visit (Visit 1) will be eligible
        to participate in the trial:

          1. Signed written informed consent;

          2. Males and females 18 to 75 years of age, inclusive;

          3. Females of childbearing potential must agree to use 2 adequate forms of barrier method
             contraception (eg, latex condom AND intrauterine device or a diaphragm) to avoid
             pregnancy while in the study;

          4. On a stable dose (Greater than or equal to 10 weeks at the same dose) of metformin
             monotherapy (Less than or equal to 1500 mg/day or maximum tolerated dose), have an
             HbA1c greater than or equal to 7.0% and less than or equal to 10.5%; or

               -  On metformin (less than or equal to 1500 mg/day) and 1 other antidiabetic agent
                  (excluding TZD, insulin, or incretin therapies [DPP-4 inhibitors and GLP-1
                  analogues]) and have an HbA1c greater than or equal to 6.8% and less than or
                  equal to 10.0%; or

               -  Not on antidiabetic therapy (for at least 3 months prior to Visit 1) or have not
                  been on a stable dose of metformin monotherapy for 10 weeks and have an HbA1c
                  greater than or equal to 8.0% and less than or equal to 11.0%.

        Exclusion Criteria:

          1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent
             hypoglycemia;

          2. History or presence of alcoholism or drug abuse within the 2 years prior to dosing;

          3. Typical consumption of greater than or equal to 10 drinks of alcohol weekly;

          4. Presence of any of the following conditions:

               -  Significant renal impairment (glomerular filtration rate less than 60 mL/min);

               -  Diabetic gastroparesis;

               -  Active liver disease (other than asymptomatic nonalcoholic fatty liver disease),
                  cirrhosis, or symptomatic gallbladder disease;

          5. Fasting plasma glucose/blood glucose greater than 240 mg/dL (13.3 mmol/L) at Visit 3
             (Week -2) (1 laboratory retest permitted);

          6. Body mass index less than or equal to 20 kg/m2 and greater than or equal to 48 kg/m2;

          7. Systolic blood pressure &lt;100 mmHg or &gt;160 mmHg and diastolic blood pressure &lt;50 mmHg
             or &gt;100 mmHg at Visit 3 (Note: medication to control blood pressure is allowed and
             should be optimized and stabilized prior to Visit 3);

          8. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2 X the upper
             limit of normal (ULN) (1 laboratory retest permitted);

          9. Creatine phosphokinase (CPK) greater than 2 X the ULN (if not explained by muscular
             trauma or exercise) (1 laboratory retest permitted);

         10. Serum creatinine &gt;1.5 mg/dL for males (132.6 μmol/L) and 1.4 mg/dL for females (123.8
             μmol/L);

         11. Fasting triglycerides (TG) &gt;600 mg/dL (6.78 mmol/L) at Visit 3 (Week -2) (Note:
             diet/exercise and lipid-lowering medication to control elevated TG is allowed;
             medications should be optimized and stabilized prior to Visit 3);

         12. Treatment with pioglitazone or rosiglitazone within the previous 10 weeks (Visit 1);
             treatment with incretin therapy (DPP-4 inhibitors or GLP-1 analogues) within the
             previous 4 weeks (Visit 1);

         13. Treatment with any type of insulin (ie, injected or inhaled) within the previous 3
             months;

         14. Must meet other laboratory and Medical History clinical criteria. Please contact
             recruitment center for referrals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane J Plotkin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ActivX Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Hermos Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chrudim III</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holesov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melnik</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangel'sk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Soweto</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>Kwazula-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paarl</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czech Republic</country>
    <country>Guatemala</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Plotkin DJ, Lewin A, Logan D, Kato T, Kozarich J, Wei X, Vest J, Orloff D. KRP-104, A Uniquely Prandial-Targeted DPP-4 Inhibitor. Abstract and Poster # 822, Presented at: European Association for the Study of Diabetes 38th Annual Meeting, Berlin Germany, October 1-5, 2012.</citation>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>June 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2014</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted in 55 medical clinics in 6 countries: US, Guatemala, South Africa, Russia, Czech Republic, Poland. First site opened 19 October 2009.</recruitment_details>
      <pre_assignment_details>Variable screening duration to allow for wash-out of one oral therapy, optimization and stabilization of dose on metformin monotherapy (&gt;= 10 weeks);followed by 2 week placebo run-in. Fasting CBG &lt;240 mg/dL at start of run in and prior to randomization required.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Tablet</description>
        </group>
        <group group_id="P2">
          <title>Dose 1: KRP-104</title>
          <description>40 mg QD</description>
        </group>
        <group group_id="P3">
          <title>Dose 2: KRP-104</title>
          <description>80 mg QD</description>
        </group>
        <group group_id="P4">
          <title>Dose 3: KRP-104</title>
          <description>100 mg QD</description>
        </group>
        <group group_id="P5">
          <title>Dose 4: KRP-104</title>
          <description>20 mg /120 mg QD (dose switch at week12)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>all other reasons combined</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Tablet</description>
        </group>
        <group group_id="B2">
          <title>Dose 1: KRP-104</title>
          <description>40 mg QD</description>
        </group>
        <group group_id="B3">
          <title>Dose 2: KRP-104</title>
          <description>80 mg QD</description>
        </group>
        <group group_id="B4">
          <title>Dose 3: KRP-104</title>
          <description>100 mg QD</description>
        </group>
        <group group_id="B5">
          <title>Dose 4: KRP-104</title>
          <description>20 mg QD (weeks 1-12)/120 mg QD (weeks 12-24)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="80"/>
            <count group_id="B6" value="403"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="9.43"/>
                    <measurement group_id="B2" value="54.2" spread="10.59"/>
                    <measurement group_id="B3" value="55.7" spread="9.10"/>
                    <measurement group_id="B4" value="56.3" spread="9.40"/>
                    <measurement group_id="B5" value="55.5" spread="8.27"/>
                    <measurement group_id="B6" value="55.8" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guatemala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline (Week 0) to Week 24</title>
        <description>Mean Change in HbA1c (%) from Baseline to Week 24 with LOCF, ITT population LS mean (SE)</description>
        <time_frame>Week 24</time_frame>
        <population>Conducted analyses of ITT population of change in HbA1c from baseline (Week 0) to Week 24. If the Wk 24 measurement was missing, the last valid post-baseline observation (LOCF) algorithm was used to impute Week 24 value (1 on-treatment value required). Efficacy data collected after the initiation of rescue therapy was excluded from the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tablet</description>
          </group>
          <group group_id="O2">
            <title>Dose 1: KRP-104</title>
            <description>40 mg QD</description>
          </group>
          <group group_id="O3">
            <title>Dose 2: KRP-104</title>
            <description>80 mg QD</description>
          </group>
          <group group_id="O4">
            <title>Dose 3: KRP-104</title>
            <description>100 mg QD</description>
          </group>
          <group group_id="O5">
            <title>Dose 4: KRP-104</title>
            <description>20 mg QD (weeks 1-12)/120 mg QD (weeks 12-24)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline (Week 0) to Week 24</title>
          <description>Mean Change in HbA1c (%) from Baseline to Week 24 with LOCF, ITT population LS mean (SE)</description>
          <population>Conducted analyses of ITT population of change in HbA1c from baseline (Week 0) to Week 24. If the Wk 24 measurement was missing, the last valid post-baseline observation (LOCF) algorithm was used to impute Week 24 value (1 on-treatment value required). Efficacy data collected after the initiation of rescue therapy was excluded from the analyses.</population>
          <units>% HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.097" lower_limit="-.28" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.41" spread="0" lower_limit="-0.60" upper_limit="-0.22"/>
                    <measurement group_id="O3" value="-0.70" lower_limit="-0.89" upper_limit="-0.51"/>
                    <measurement group_id="O4" value="-0.71" lower_limit="-0.89" upper_limit="-0.52"/>
                    <measurement group_id="O5" value="-0.73" lower_limit="-0.92" upper_limit="-0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Mean Change in Body Weight (kg) from Baseline to Week 24 with LOCF- ITT</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tablet</description>
          </group>
          <group group_id="O2">
            <title>Dose 1: KRP-104</title>
            <description>40 mg QD</description>
          </group>
          <group group_id="O3">
            <title>Dose 2: KRP-104</title>
            <description>80 mg QD</description>
          </group>
          <group group_id="O4">
            <title>Dose 3: KRP-104</title>
            <description>100 mg QD</description>
          </group>
          <group group_id="O5">
            <title>Dose 4: KRP-104</title>
            <description>20 mg QD (weeks 1-12)/120 mg QD (weeks 12-24)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Mean Change in Body Weight (kg) from Baseline to Week 24 with LOCF- ITT</description>
          <units>kg body weight on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.303"/>
                    <measurement group_id="O2" value="-1.13" spread="0.303"/>
                    <measurement group_id="O3" value="-1.31" spread="0.302"/>
                    <measurement group_id="O4" value="-0.70" spread="0.300"/>
                    <measurement group_id="O5" value="-0.18" spread="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving HbA1c Less Than 7%</title>
        <description>Subjects Achieving Target of Hemoglobin A1c &lt;7.0% at Week 24 with LOCF – Intent-to-Treat Population</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tablet</description>
          </group>
          <group group_id="O2">
            <title>Dose 1: KRP-104</title>
            <description>40 mg QD</description>
          </group>
          <group group_id="O3">
            <title>Dose 2: KRP-104</title>
            <description>80 mg QD</description>
          </group>
          <group group_id="O4">
            <title>Dose 3: KRP-104</title>
            <description>100 mg QD</description>
          </group>
          <group group_id="O5">
            <title>Dose 4: KRP-104</title>
            <description>20 mg QD (weeks 1-12)/120 mg QD (weeks 12-24)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving HbA1c Less Than 7%</title>
          <description>Subjects Achieving Target of Hemoglobin A1c &lt;7.0% at Week 24 with LOCF – Intent-to-Treat Population</description>
          <units>% of subjects in group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.08"/>
                    <measurement group_id="O2" value="31.65"/>
                    <measurement group_id="O3" value="49.37"/>
                    <measurement group_id="O4" value="43.75"/>
                    <measurement group_id="O5" value="41.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Requiring Rescue Therapy for Elevated Glucose</title>
        <description>Percentage of Subjects Requiring Rescue Therapy – Intent-to-Treat Population</description>
        <time_frame>24 weeks of treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Tablet</description>
          </group>
          <group group_id="O2">
            <title>Dose 1: KRP-104</title>
            <description>40 mg QD</description>
          </group>
          <group group_id="O3">
            <title>Dose 2: KRP-104</title>
            <description>80 mg QD</description>
          </group>
          <group group_id="O4">
            <title>Dose 3: KRP-104</title>
            <description>100 mg QD</description>
          </group>
          <group group_id="O5">
            <title>Dose 4: KRP-104</title>
            <description>20 mg QD (weeks 1-12)/120 mg QD (weeks 12-24)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Requiring Rescue Therapy for Elevated Glucose</title>
          <description>Percentage of Subjects Requiring Rescue Therapy – Intent-to-Treat Population</description>
          <units>% of subjects in group</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="5.06"/>
                    <measurement group_id="O4" value="3.75"/>
                    <measurement group_id="O5" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first site open on 19 October 2009 through 30 days after last subject out on 20 January 2011, approximately 1 year 5 months.</time_frame>
      <desc>Only treatment related adverse events were reported in the clinical study report. There were no occurrences of serious adverse events that were considered related to drug, thus none met criterion of reportable event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Tablet</description>
        </group>
        <group group_id="E2">
          <title>Dose 1: KRP-104</title>
          <description>40 mg QD</description>
        </group>
        <group group_id="E3">
          <title>Dose 2: KRP-104</title>
          <description>80 mg QD</description>
        </group>
        <group group_id="E4">
          <title>Dose 3: KRP-104</title>
          <description>100 mg QD</description>
        </group>
        <group group_id="E5">
          <title>Dose 4: KRP-104</title>
          <description>20 mg QD (weeks 1-12)/120 mg QD (weeks 12-24)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>not related, start= day 119</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystolithiasis</sub_title>
                <description>not related, start=day 70</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>tuberculosis meningitis</sub_title>
                <description>not related, start date= study day 27 subject was subsequently also diagnosed with human immunodeficiency virus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Lyme Disease</sub_title>
                <description>not related, start= day 18</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>not related, start = day 121</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture Of The Left Anterior Lamina Papyracea (Ethmoid Bone)</sub_title>
                <description>not related, start= day 35</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <description>not related, start= day 86</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intractable Low Back Pain</sub_title>
                <description>not related, start= day 68</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer (left breast)</sub_title>
                <description>not related, start = study day 34</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>lung cancer</sub_title>
                <description>not related, start= day 6</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <description>study day 76, not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No explicit limitations on discussion by PI. PI may not publish results before a coordinated multicenter publication has been submitted for publication, marketing approval obtained, or until 7 years after the study has ended, whichever occurs first. Thereafter, the study site will have the opportunity to publish the results of the study, provided that the Sponsor has had the opportunity to review and comment on the study site’s proposed publication prior to it being submitted for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Diane Plotkin, Sr. Director Clinical Development</name_or_title>
      <organization>ActivX Biosciences</organization>
      <phone>858-558-5558</phone>
      <email>dianep@activx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

